CashuMetaVia Strengthens IP Portfolio for Innovative Cardiometabolic Disease Solutions with Vanoglipelabout 10 hours ago
CashuMetaVia Expands IP Portfolio to Enhance Treatment of Metabolic Diseases with Vanoglipel2 days ago
CashuMetaVia Advances Innovative Therapies for Cardiometabolic Diseases Ahead of Investor Forum7 days ago
prnewswire.comMetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 20351 day ago
prnewswire.comMetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum9 days ago
prnewswire.comMetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference24 days ago
prnewswire.comMetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 204128 days ago
prnewswire.comMetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Optionabout 2 months ago
prnewswire.comMetaVia Announces the Pricing of $8.1 Million Underwritten Public Offeringabout 2 months ago
prnewswire.comMetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile2 months ago